The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s disease
Open accessPublished version of a preprint
Abstract
Abstract Cell stress and impaired oxidative phosphorylation are central to mechanisms of synaptic loss and neurodegeneration in the cellular pathology of Alzheimer’s disease (AD). We quantified the in vivo density of the endoplasmic reticulum stress marker, the sigma 1 receptor (S1R) using [ 11 C]SA4503 PET, as well as that of mitochondrial complex I (MC1) with [ 18 F]BCPP-EF and the pre-synaptic vesicular protein SV2A with [ 11 C]UCB-J in 12 patients with early AD and in 16 cognitively normal controls. We integrated these molecular measures with assessments of regional brain volumes and brain perfusion (CBF) measured with MRI arterial spin labelling. 8 AD patients were followed longitudinally to estimate rates of change with disease progression over 12-18 months. The AD patients showed widespread increases in S1R (≤ 27%) and regional decreases in MC1 (≥ -28%), SV2A (≥ -25%), brain volume (≥ -23%), and CBF (≥ -26%). [ 18 F]BCPP-EF PET MC1 density (≥ -12%) and brain volumes (≥ -5%) were further reduced at follow up in brain regions consistent with the differences between AD patients and controls at baseline. Exploratory analyses showing associations of MC1, SV2A and S1R density with cognitive changes at baseline and longitudinally with AD, but not in controls, suggested a loss of metabolic functional reserve with disease. Our study thus provides novel in vivo evidence for widespread cellular stress and bioenergetic abnormalities in early AD and that they may be clinically meaningful.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Human in vivo studies with synaptic vesicle glycoprotein 2a–binding PET ligands confirm this loss of synaptic density. 54”
From Alzheimer's disease and its progression reduce pyramidal cell gain and connectivity (2025) · cites this paper as [54]
Citations
Cites
Advances in functional and structural MR image analysis and implementation as FSL
Smith, S. M., Jenkinson, M., Woolrich, M. W., Beckmann, C. F., Behrens, T. E. J., Johansen-Berg, H., Bannister, P. R., De Luca, M., Drobnjak, I., Flitney, D. E., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.051 · Cited by 13,630
Self-citationJenkinson, M., Bannister, P., Brady, M., & Smith, S. (2002) · NeuroImage · doi:10.1006/nimg.2002.1132 · Cited by 11,888
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Cognitive reserve in ageing and Alzheimer's disease
Stern, Y. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70191-6 · Cited by 3,557 · cited 1×
“The healthy brain thus has considerable functional reserve arising from a redundancy or plasticity that allows normal cognition to be maintained despite some impairments of functions (those affecting metabolism and synaptic and neuronal circuit activity) (20).”
BackgroundPhases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Single-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Cited by
Sorted by citations
Items 101–104 of 104
Sigma-1 Receptor Ligand Blarcamesine (ANAVEX 2-73) for Alzheimer’s Disease: A Systematic Review
Brimson, S., Thitilertdecha, P., Kumaree, K., & Brimson, J. (2026) · CNS Drugs · doi:10.1007/s40263-026-01327-3
Mitochondrial dysfunction in neurodegenerative diseases: Mechanisms and therapeutic advances
Yao, Z., Wei, Y., Xie, W., Gao, R., Zhan, Y., Wu, X., Zhang, W., Pei, Y., Zhang, G., & Wang, Z. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103312
Hussain, J. M., Lashari, A., Nageen, W., Siddiqui, A., Waris, A., Maliha, S., Mudasir, A., Rehman, M. B. A., & Rahman, M. H. U. (2026) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2025-0412
Zhang, J., Yu, Z., Zhang, X., & Wang, H. (2026) · npj Dementia · doi:10.1038/s44400-026-00124-5
Metadata
- Authors
- Venkataraman, A. V., Mansur, A., Rizzo, G., Bishop, C., Lewis, Y., Kocagoncu, E., Lingford-Hughes, A., Huiban, M., Passchier, J., Rowe, J. B., Tsukada, H., Brooks, D. J., Martarello, L., Comley, R. A., Chen, L., Schwarz, A. J., Hargreaves, R., Gunn, R. N., Rabiner, E. A., & Matthews, P. M.
- Affiliations
- UK Dementia Research Institute (GB)
- Invicro (United Kingdom) (GB)
- University of Cambridge, Cambridge CB2 2QQ, UK.
- Imperial College London (GB)
- Invicro LLC, London W12 0NN, UK.
- University of Cambridge (GB)
- Hamamatsu Photonics (Japan) (JP)
- Aarhus University (DK)
- Biogen (United States) (US)
- AbbVie (United States) (US)
- Pfizer (United States) (US)
- Takeda Pharmaceuticals Ltd, Cambridge, MA 02139, USA.
- Bristol-Myers Squibb (United States) (US)
- King's College London (GB)
- Corresponding author
- Matthews, Paul M.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2022-08-17
- Volume
- 14
- Issue
- 658
- Pages
- eabk1051-eabk1051
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W4292266434
- Cited by
- 101
- References
- 64
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 32 · 2023: 17 · 2022: 2
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Science Translational Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Alzheimer's Society
- National Institute for Health and Care Research (BRC1215-20014, NIHR-INF-0507, CL-2022-17-003)
- Department of Health and Social Care
- Imperial College London
- UK Dementia Research Institute
- Medical Research Council (MR/N029941/1, MR/L023784/2, SUAG/051 G101400, G101400, BRC-1215-20014, MR/T033371/1)
- NIHR Cambridge Biomedical Research Centre ((BRC-1215-20014))
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- early Alzheimer's disease, endoplasmic reticulum stress, sigma-1 receptor, mitochondrial complex I, oxidative phosphorylation, mitochondrial dysfunction, SV2A, presynaptic dysfunction, brain atrophy, cerebral blood flow, disease progression, pharmacodynamic biomarkers, cognitive decline
- MeSH terms
- Alzheimer Disease, Brain, Cerebrovascular Circulation, Humans, Magnetic Resonance Imaging, Mitochondria, Biomarkers, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
